Form 4: Olema Pharmaceuticals CEO Awarded Stock Options
SEC Form 4 Filing
Olema Pharmaceuticals' CEO, Sean Bohen, was granted stock options for 650,000 shares on February 28, 2025, as reported in a Form 4 filing with the SEC.
Summary
- Sean Bohen, the President and CEO of Olema Pharmaceuticals, was granted stock options to purchase 650,000 shares of common stock.
- The options were granted on February 28, 2025, with an exercise price of $4.37 per share.
- The options vest over time, with 25% vesting on February 28, 2026, and the remaining 75% vesting monthly over the subsequent 36 months, contingent upon continuous service.
- The options expire on February 27, 2035.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and suggests confidence in the company's future performance. The vesting schedule promotes long-term alignment.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule incentivizes long-term commitment and performance from the CEO.
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and align management's interests with those of shareholders. The size and vesting schedule of the grant are typical considerations.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their executive compensation strategy.
- The vesting schedule of these options, typically over 3-4 years, is consistent with industry norms.
Stakeholder Impact
- Shareholders: The stock option grant aligns the CEO's interests with increasing shareholder value.
- Employees: The grant may boost employee morale by demonstrating confidence in the company's leadership and future prospects.
Key Dates
| Date | Description |
|---|---|
| 02/28/2025 | Date of earliest transaction (grant date of stock options) |
| 02/28/2026 | 25% of the shares subject to the option vest |
| 02/27/2035 | Expiration date of the stock options |
| 03/03/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.